This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
AVEO Stops AML Study on Ficlatuzumab Amid Coronavirus Pandemic
by Zacks Equity Research
AVEO ceases the phase II CyFi-2 study on ficlatuzumab plus high-dose cytarabine for treating patients with relapsed/refractory acute myeloid leukemia to combat the COVID-19 outbreak.
AstraZeneca's Imfinzi Gets FDA Nod for SCLC Label Expansion
by Zacks Equity Research
AstraZeneca's (AZN) Imfinzi gets FDA approval as first-line treatment for extensive-stage small cell lung cancer patients. A phase III study on Farxiga in CKD patients meets endpoint earlier than expected.
Bristol Myers (BMY) Clinches FDA Nod for MS Drug Zeposia
by Zacks Equity Research
The FDA approves Bristol Myers' (BMY) Zeposia for the treatment of adults with relapsing forms of multiple sclerosis.
Zacks Value Trader Highlights: eBay, Pfizer, JPMorgan Chase, Intuitive Surgical and Edwards Lifesciences
by Zacks Equity Research
Zacks Value Trader Highlights: eBay, Pfizer, JPMorgan Chase, Intuitive Surgical and Edwards Lifesciences
Pharma, Biotech Players Step Up Efforts Against Coronavirus
by Indrajit Bandyopadhyay
Several pharma & biotech companies announce their plan to fight coronavirus pandemic and state anticipated unfavorable impact of the outbreak on their business.
AstraZeneca's Lokelma Gets Approval in Japan for Hyperkalaemia
by Zacks Equity Research
The Japanese regulatory body nods to AstraZeneca's (AZN) Lokelma for addressing patients with hyperkalaemia. The company collaborates with Silence Therapeutics for siRNA therapeutics.
5 Superstar Stocks on Sale During the Coronavirus Crisis
by Tracey Ryniec
Stocks are the only thing people won't buy when they go on sale. But with stocks in a bear market, now's your chance to pick up some of the best companies.
Pfizer (PFE) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed at $29.75 in the latest trading session, marking a +0.17% move from the prior day.
Pfizer's Eczema Drug Eucrisa Gets FDA Approval for Infants
by Zacks Equity Research
Pfizer (PFE) gets FDA approval for label expansion of Eucrisa to include children aged three months to two years with mild-to-moderate atopic dermatitis or eczema.
Glaxo's Long-Acting HIV Regimen Cabenuva Gets Canada's Nod
by Kinjel Shah
Glaxo's (GSK) long-acting injectable regimen of cabotegravir and rilpivirine gets its first approval for the treatment of HIV-1 infection in virologically-suppressed adults
The Zacks Analyst Blog Highlights: Pfizer, Roche, Sanofi, Lilly and Merck
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, Roche, Sanofi, Lilly and Merck
The Zacks Analyst Blog Highlights: Macy's, AbbVie, Pfizer and New Residential Investment
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Macy's, AbbVie, Pfizer and New Residential Investment
Pharma Stock Roundup: SNY, RHHBY, PFE's Coronavirus Product Development & Other Updates
by Kinjel Shah
Pfizer (PFE) is set to jointly develop BioNTech's potential coronavirus vaccine. Regeneron/Sanofi (SNY) and Roche will study their RA drugs, Kevzara & Actemra, respectively to treat severe COVID-19 infection.
4 Dividend Stocks to Buy Amid the Coronavirus Rout
by Nitish Marwah
The coronavirus has dealt a huge blow to markets globally. Valuations have gone for a toss across every asset class and sector.
Pfizer's Eczema Drug & Pneumococcal Vaccine Succeed in Study
by Zacks Equity Research
Pfizer's (PFE) atopic dermatitis (eczema) candidate, abrocitinib, and pneumococcal conjugate vaccine candidate meet primary endpoints in their respective late-stage studies.
Pfizer (PFE) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed the most recent trading day at $32.40, moving +0.75% from the previous trading session.
Merck's Chronic Cough Candidate Achieves Goals in Phase III
by Zacks Equity Research
Merck's (MRK) two phase III studies on gefapixant (MK-7264) for the treatment of refractory or unexplained chronic cough meet the primary efficacy endpoints.
Pfizer, Regeneron Give Update on Coronavirus Drug Development
by Kinjel Shah
Pfizer (PFE) to jointly develop BioNTech's potential coronavirus vaccine. Regeneron (REGN) could start clinical studies of a COVID-19 therapy by this summer.
Company News for Mar 18, 2020
by Zacks Equity Research
Companies In The News Are: PFE, BNTX, REGN, DNKN. TMO.
Lilly's Olumiant Gets Breakthrough Therapy Tag for Hair Loss
by Zacks Equity Research
The FDA grants breakthrough therapy status to Eli Lilly's (LLY) oral JAK inhibitor, Olumiant (baricitinib) for potential treatment of alopecia areata, an autoimmune disorder leading to hair loss.
Moderna Up as First Human Trial of Coronavirus Vaccine Begins
by Zacks Equity Research
Moderna (MRNA) announces dosing of first human in a phase I clinical study evaluating its coronavirus vaccine candidate. The National Institutes of Health is conducting the study.
Pfizer (PFE) Catches Eye: Stock Jumps 9%
by Zacks Equity Research
Pfizer (PFE) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Emergent BioSolutions Collaborates for Coronavirus Vaccine
by Zacks Equity Research
Emergent BioSolutions' (EBS) collaborates with Novavax to support production of the latter's coronavirus vaccine and advance it to clinical stage development.
Mylan-Upjohn Merger in Focus, Coronavirus Might Hit Supply
by Zacks Equity Research
Mylan's (MYL) merger with Upjohn is in focus as the former looks to revive its business. However, the coronavirus epidemic can hit the company's supply-chain operations.
Allergan's (AGN) Glaucoma Implant Durysta Gets FDA Approval
by Zacks Equity Research
Allergan's (AGN) Durysta (bimatoprost) gets FDA approval to reduce intraocular pressure in patients with open-angle glaucoma.